You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. OPTIMIZATION AND ASSESSMENT OF A BIOLOGIC TO IMPROVE FUNCTIONAL RECOVERY AFTER PERIPHERAL NERVE INJURY

    SBC: ALCAMENA STEM CELL THERAPEUTICS, LLC            Topic: NINDS

    ABSTRACT. Peripheral nerve injury (PNI) is a common and challenging clinical problem affecting over 3% of U.S. trauma patients. Among combat trauma, the rate of PNI increases to 22%. These patients require extensive resources for initial treatment and therapy, yet they are still left with functional disability. Current treatments for motor, sensory, and mixed PNI include nerve autografts and axona ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Intelligent Biometrics to Optimize Prolonged Exposure Treatment for PTSD (IB-PE)

    SBC: Zeriscope, Inc.            Topic: 104

    PROJECT SUMMARY/ABSTRACT Posttraumatic Stress Disorder (PTSD) is a debilitating disease affecting millions of American military veterans and civilians. Prolonged Exposure (PE) therapy is evidence-based and effective but limited by high dropout rates and incomplete resolution of symptoms in approximately one-third of patients. A crucial component of PE, as well as interventions for anxiety disorder ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease

    SBC: Rise Therapeutics, LLC            Topic: NIAID

    Project Summary The goal of this project is to commercialize a novel, immunologically-enhanced version of Lactobacillus acidophilus for the treatment of inflammatory bowel disease (IBD). Over 1.6 million adults and children in the United States suffer from IBD, an umbrella term encompassing two chronic inflammatory diseases of the gastrointestinal tract: Crohnandapos;s disease (CD) and ulcerative ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins

    SBC: GLYCOT THERAPEUTICS LLC            Topic: 300

    Project abstract/summary This proposal responds to the NIH PA-16-157 “New Technologies for the Glycosciences (R43/R44)”. We aim to develop efficient and streamlined cheomoenzymatic systems for glycan remodeling of antibodies and other important glycoproteins, through optimizing enzyme immobilization and simplifying the reaction procedures. Such immobilized enzymes, when combined with activated ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Preventing Opioid Exposure Training (POET) for First Responders

    SBC: GRYPHON SCIENTIFIC, LLC            Topic: 142

    PROJECT SUMMARY/ABSTRACT In this competitive revision Phase I SBIR, Gryphon Scientific proposes to expand the scope of the ongoing project to support the urgent need to develop and deploy training for first responder populations at risk of exposure to the novel coronavirus (COVID-19). The ongoing Phase I SBIR project focuses on training first responders (including law enforcement, fire, and EMS pe ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Mining natively paired macque antibodies for Marburg virus protective antibodies

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project summary Filoviruses are among the deadliest known human viruses. The family Filoviridae contains two clinically relevant genera; Ebolavirus and Marburgvirus that each consist of multiple viruses. Filoviruses have caused 48 outbreaks since Marburg virus was discovered in 1967. Marburgvirus has caused 13 outbreaks, 5 of which occurred in the past 10 years with an average lethality of 81%. Th ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Evaluation of a Novel Connexin-Based Peptide in the Treatment of Combined Ionizing Radiation and Thermal Burn Injury

    SBC: FirstString Research, Inc            Topic: NIAID

    PROJECT SUMMARYThe threat of a nuclear attack or disaster resulting in mass casualties is of increasing concernRadiation injury frequently occurs in combination with thermal burnsCombined radiation and thermal burn injuryCRBIresults in impaired wound healingexacerbated symptomsand synergistic increases in mortalityCountermeasures that synergistically address the complex pathophysiology of CRBI at ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A Cloud-Based Web Application to Accelerate Targeted Covalent Drug Discovery

    SBC: COMPUTCHEM, LLC            Topic: 400

    Project Summary Abstract Covalent drug discovery is gaining increasing interest and clinical successespecially for cancer and infectious diseasesAlthough old covalent drugs were discovered serendipitouslymodern covalent drug discovery takes a rational approachWhile chemical intuition and trial and error are helpfulthe discovery process can be signi cantly shortened by the knowledge of whether the ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Whole-Cell Vaccine Development for MRSA

    SBC: BIOLOGICAL MIMETICS, INC.            Topic: NIAID

    AbstractMethicillin resistant Staphylococcus aureusMRSAis one of the leading causes of many life threatening infections such as skin and soft tissue sepsispneumoniaosteomyelitis and endocarditisDue to the growing incidence of multiple drug resistance in Saureus strains and the absence of effective new antibioticstreatment options are becoming increasingly limitedDifficulties in developing new anti ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. ISTAb- A novel therapy to target staphylococcal toxins at the site of infections

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Many bacterial pathogens secrete exotoxins to modify the host-pathogen interactions in a manner that benefits the bacteria. There are several examples of successful prophylaxis and treatment by targeting bacterial toxins as evident by decades-long history of vaccines for tetanus, diphtheria, and pertussis. Staphylococcus aureus (SA) is a major human pathogen responsible for several ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government